secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vivos Therapeutics, Inc. (VVOS)
CIK:        0001716166
Form:       8-K
Filed at:   2025-06-06T23:59:59+00:00
Accession:  0001641172-25-014118
Event type: other_material
Sentiment:  neutral
Materiality: 0.20
Item codes: 4.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vivos Therapeutics appoints Baker Tilly as independent auditor after Moss Adams merger
--------------------------------------------------------------------------------

- Moss Adams merged into Baker Tilly effective June 3, 2025; Moss Adams resigned as auditor.
- Audit committee approved Baker Tilly as successor independent registered public accounting firm.
- No disagreements or reportable events between Vivos and Moss Adams during 2023, 2024, or through June 3, 2025.
- Moss Adams' prior audit reports contained an explanatory paragraph regarding going concern uncertainty.
- No consultations with Baker Tilly on accounting principles or disagreements occurred before appointment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1716166/000164117225014118/0001641172-25-014118-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1716166/000164117225014118/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-014118

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer